GlassScriptPhysician profile
Clarke Alan Low
NPI 1063787315
$3,536.74
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $17.24 · 2021: $1,985 · 2024: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,410.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,984.50 | 2021 | |
| Daiichi Sankyo INC. | $1,410.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarke Low listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.